Comparing tumour heterogeneity in primary tumour, circulating tumour cells and metastases

No registrations found.

Ethical review	Not applicable
Status	Other
Health condition type	-
Study type	Interventional

Summary

ID

NL-OMON29203

Source
Nationaal Trial Register

Brief title
CTC Autopsy study

Health condition

NSCLC niet kleincellig longcarcinoom, longkanker
lungcancer, tumour heterogeneity, tumor heterogeniteit, CTC, circulating tumour cell, circulerende tumor cel

Sponsors and support

Primary sponsor: University Medical Centre Groningen
Source(s) of monetary or material Support: University Medical Centre Groningen

Intervention

Outcome measures

Primary outcome

- heterogeneity and mutational load measurements in all compartments. These can

subsequently be compared to one another.

Secondary outcome

-

Study description

Study objective

NSCLC spreads using the blood. Tumour cells in the circulating system are called circulating tumour cells, and are deemed the cause of metastases, making CTCs a mayor factor in therapy efficacy and prognosis. We believe that the different compartments (original tumour, metastases and CTCs) will have differences in the genetic make up that could give insight in the metastatic process and shed light on so called 'trunc' and 'branch' mutations. To study all different compartments in detail, we will ask terminal patients to participate in a so called obduction study. After a patients death, we will obtain biopsies of the metastases and the primary tumour. When this is done the patients body will be returned to the family for burial.

Study design

-

Intervention

Terminal patients are included after their informed consent and that of their families is received. We will withdraw some blood for analysis on CTCs. After the participants death, we will perform a warm autopsy to obtain samples from the primary tumour and its metastases. The patients body will subsequently be returned to the family for burial.

Contacts

Public
UMCG
Department of Pulmonary Disease, Box 30001
H.J.M. Groen
Groningen 9700 RB
The Netherlands
+31 (0)50 3616161
Scientific
UMCG

Department of Pulmonary Disease, Box 30001
H.J.M. Groen
Groningen 9700 RB
The Netherlands
+31 (0)50 3616161

Eligibility criteria

Inclusion criteria

1. Patients with a histologically/cytologically proven pulmonary malignancy.

2. Patients have to have a non-curable disease state, without curative treatment options

3. Signed informed consent

4. Patients family has asserted their acceptance of the patients participation

5. Patients using anticoagulants such as fraxodi or acenocoumarol are allowed

Exclusion criteria

1. No growth factor medication

Study design

Design

Study type:	Interventional
Intervention model:	Other
Masking:	Open (masking not used)
Control:	N/A , unknown

Recruitment

NL
Recruitment status: Other

Start date (anticipated):	01-10-2016
Enrollment:	30
Type:	Unknown

Ethics review

Not applicable
Application type: Not applicable

Study registrations

Followed up by the following (possibly more current) registration

ID: 45251
Bron: ToetsingOnline
Titel:

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
NTR-new	NL5862
NTR-old	NTR6042
CCMO	NL59037.042.16
OMON	NL-OMON45251

Study results